6 research outputs found
15. Recombinant human hyaluronidase pretreatment of CSII cannula sites provides comparable glycemic control with reduced hypoglycemia in T1DM compared to usual CSII (85-LB)
No full textRecombinant human hyaluronidase (rHuPH20) is FDA-approved to increase dispersion and absorption of injected drugs. In CSII, a single pretreatment of the cannula site with rHuPH20 accelerates exposure and action of bolus doses of rapid analogs for up to 3 days of catheter use
High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.
No full textBaseline plasma HA in PDA versus healthy subjects and effects of PEGPH20 on plasma HA in PDA subjects treated with GEM/NAB.
No full textFinal analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.
No full text
